Financial Solutions Advisory Group Inc. Purchases Shares of 17,177 Novo Nordisk A/S $NVO

Financial Solutions Advisory Group Inc. purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 1st quarter, Holdings Channel.com reports. The institutional investor purchased 17,177 shares of the company’s stock, valued at approximately $631,000.

Several other large investors have also bought and sold shares of NVO. Revolve Wealth Partners LLC grew its position in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the period. AQR Capital Management LLC boosted its stake in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after acquiring an additional 10,758 shares during the last quarter. Sivia Capital Partners LLC grew its position in shares of Novo Nordisk A/S by 18.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock valued at $712,000 after acquiring an additional 1,587 shares during the period. Invesco Ltd. increased its stake in shares of Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after purchasing an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $314,000. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Finally, Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Five analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s existing obesity business remains a key support. The company recently received European approval for a once-daily Wegovy pill and partnered with Crux to expand access to Wegovy through U.S. employer health plans, potentially broadening distribution and affordability. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Neutral Sentiment: Some investor commentary indicates that Novo Nordisk’s current revenue drivers, particularly its GLP-1 medicines, remain intact despite the pipeline setback. However, the failed trial increases reliance on those products for future growth. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
• Negative Sentiment: In the Phase 3 ZEUS trial, ziltivekimab failed to significantly reduce major adverse cardiovascular events versus placebo in patients with cardiovascular disease, chronic kidney disease and inflammation. The result eliminates or reduces the near-term commercial potential of a drug intended to expand Novo Nordisk’s cardiovascular portfolio. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
• Negative Sentiment: The setback is weighing on investor confidence in Novo Nordisk’s pipeline and has pushed the stock lower as markets reassess future growth and valuation. Novo Nordisk Shares Dive After Heart Medicine Fails Trial
• Negative Sentiment: Erste Group Bank also trimmed its fiscal 2026 earnings estimate to $3.20 per share from $3.22, below the $3.39 consensus estimate, adding to the cautious outlook. Novo Nordisk Analyst Estimate Update

Novo Nordisk A/S Price Performance

NVO opened at $47.20 on Friday. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock has a 50-day moving average price of $46.92 and a 200-day moving average price of $45.50. The stock has a market capitalization of $210.74 billion, a P/E ratio of 11.08, a PEG ratio of 4.30 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.